Critical Illness Clinical Trial
Official title:
Team Sepsis: Fast I(n)Dentification of PATHogens (FINDPATH)
Sepsis is the body-wide response to infection. People who develop sepsis have an increased risk of dying. One of the greatest challenges in sepsis is determining what is the pathogen (bacteria or virus for example) in a timely manner so the most specific antibiotics can be given to treat the infection. Patients presenting to the hospital and the intensive care unit often have lung infections. In this study the investigators plan to develop new techniques to rapidly (less than 6 hours) identify bacteria growing in the airways of patients on ventilators. The investigators will obtain these samples by suctioning the airways (a routine procedure) and comparing the bacterial cultures grown by novel culture media with the usual techniques in the hospital microbiology laboratory. At the same time the investigators will collect a blood sample. This blood sample will be used to isolate the bacterial genetic material and use this to compare with bacteria grown on the culture media from the clinical and the research laboratory. The investigators will also collect information on the patient's course in hospital. These pilot study results will allow us to integrate this new technique into routine patient care.
The trial design is a pilot observational feasibility study within three intensive care units
at the Hamilton General Hospital, which is composed of both medical and surgical patient
populations where waived consent has been confirmed and approved by the Hamilton Integrated
Research Ethics Board. The study sample will include 50 patients over the age of 16 that will
be mechanically ventilated for greater than 48 hours with no antibiotic use for the past 24
hours and meet the Johanson Criteria for Ventilator Associated Pneumonia (VAP) as the gold
standard for diagnosis still remain controversial. This Johanson criteria maintains patients
must have 2 out of three criteria to be enrolled in the study and that criteria includes
either a leukocyte count >12,000/mm³ , Fever >38.0ºC and/or a new onset of purulent
endotracheal secretions or change in the character of sputum. Chest x-rays for examination of
a new or progressing infiltrate will be assessed but will not be used for initial inclusion
criteria but possibly in the conclusions when attempting to differentiate VAP from VAT.
Recruitment of eligible patients maintains the need for daily screening of patients which
will be done primarily by myself as the co-investigator and from a research assistant through
the secure hospital patient data system. However education of the frontline staff
particularly nursing, respiratory therapists, physiotherapists and staff physicians who will
have direct contact with potential subject is also essential for successful recruitment,
coordination and timing of enrollment. I will create and hold education sessions for all
frontline staff outlining the purpose of the study, patient enrollment criterion and proper
sample collection procedures as well as continual bedside education throughout the course of
the study to ensure all staff will have the information to identify potential study patients.
Once patients are identified as meeting criteria for enrollment, the research assistant will
be notified at which time the frontline staff will retrieved a premade package for the sample
collection. Using a sterile catheter and a clean technique, two separate tracheal aspirates
will be acquired from the subject and placed in their specialized clinical or research sputum
trap. To acquire two samples, sterile saline irrigation will be permitted and if needed the
splitting of the specimen into the separated collection traps. Concurrently a tube of blood
as well as one set of blood cultures from an established indwelling access (either central
line, arterial line or peripheral blood draw) will be drawn. Clinical lab labels will be
placed on one sputum sample and the set of blood cultures and sent routinely to the
microbiology lab. The research lab bag will contain the second sputum sample and blood tube
labelled with patient identification number and the time of sample collection. To ensure the
ability of culturing for anaerobic bacteria in the research laboratory, an anaerobic pack
will be placed in the research sample bag with the sputum sample and blood tube as well as a
damp paper towel. The sample bag will then be voided of air and sealed. The research bag is
labelled as well with patient identification number and date/time of sample collection which
is then sent to the clinical microbiology lab. The clinical laboratory is then notified of
the incoming research sample which will need to be transported to the research laboratory via
established laboratory transportation protocols. Once the sample is sent, the co-investigator
is notified again and clinical data (leukocytes, hemoglobin, platelets, arterial blood gases,
temperature, Glasgow coma scale, oxygen requirements, high/low respiratory rate, heart rate,
and blood pressure) for the day of collection and for the following six days including
complete ICU antibiotic usage, extubation date and final patient outcome after 30 days can be
collected and entered into a secure RedCap database. Communication to the research laboratory
will be the responsibility of the co-investigator to ensure samples have arrived and can be
plated in the time set out within the study protocol. Transportation of the samples are
available from 0700 until 2000 Monday through Sunday so identification of potential
enrollment , and collection of samples will be encouraged during these times to ensure
successful arrival and processing of samples at the research laboratory.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04551508 -
Delirium Screening 3 Methods Study
|
||
Recruiting |
NCT06037928 -
Plasma Sodium and Sodium Administration in the ICU
|
||
Completed |
NCT03671447 -
Enhanced Recovery After Intensive Care (ERIC)
|
N/A | |
Recruiting |
NCT03941002 -
Continuous Evaluation of Diaphragm Function
|
N/A | |
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Completed |
NCT04239209 -
Effect of Intensivist Communication on Surrogate Prognosis Interpretation
|
N/A | |
Completed |
NCT05531305 -
Longitudinal Changes in Muscle Mass After Intensive Care
|
N/A | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Completed |
NCT02916004 -
The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients.
|
N/A | |
Recruiting |
NCT05883137 -
High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
|
||
Completed |
NCT04479254 -
The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study)
|
N/A | |
Recruiting |
NCT04475666 -
Replacing Protein Via Enteral Nutrition in Critically Ill Patients
|
N/A | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Withdrawn |
NCT04043091 -
Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction
|
N/A | |
Recruiting |
NCT02989051 -
Fluid Restriction Keeps Children Dry
|
Phase 2/Phase 3 | |
Recruiting |
NCT02922998 -
CD64 and Antibiotics in Human Sepsis
|
N/A | |
Completed |
NCT03048487 -
Protein Consumption in Critically Ill Patients
|
||
Completed |
NCT02899208 -
Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients?
|
N/A | |
Recruiting |
NCT02163109 -
Oxygen Consumption in Critical Illness
|